IN8bio, Inc. Common Stock
XNAS:INAB
1.77
$7.05 - 26.00
$1.75 - 33.00
$1.77
$1.88
$1.85
$1.82
12.53
1.53
26153
55695.9
4191685.04
Chart
TendieTensor AI Analysis
Company
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Fundamentals
18
-0.270000
0.615884
-0.85
100
BBG00XX9K1M2
BBG00XX9K2G7
4.54M
4.54M
Technicals
Short Interest
—
—
—
Higher = harder to cover
—
Prev: —
—
—
5D avg: —
—
Discussion
Login to participate in discussions.
Recent News
Related Stocks
Based on the portfolios of people who own INAB. This is a list generated by trading data from 3rd party trading platforms, and it's not a recommendation.